MIDDLESEX WATER CO (MSEX) stock intrinsic value fair value estimate & owner earnings analysis

Middlesex Water is a regulated water and wastewater utility founded in 1897. Its main business is the Middlesex System in central New Jersey, which sells water to homes and businesses and under long-term contracts to neighbouring towns, plus Pinelands in Burlington County, New Jersey, and Tidewater and Southern Shores in Delaware. Rates are set by the New Jersey Board of Public Utilities and the Delaware Public Service Commission so that the company recovers its operating costs, depreciation and interest and earns an authorized return on the capital it has invested. In February 2026 New Jersey approved a $14.5 million annual rate increase for Middlesex (effective February 23, 2026) on a 9.6% authorized return on equity, and Delaware approved $5.5 million for Tidewater on 9.5%. How we measure the cash. On a strict cash basis this business has not produced free cash for shareholders in any of the last ten years. Operating cash flow was $62.6 million in 2025 against $96.4 million of plant spending, and our standard formula, which treats spending beyond what revenue growth seems to require as upkeep, shows negative owner earnings every year from 2016 to 2025 (about -$1.73 a share in 2025). That reading misses how a regulated utility works: every dollar of prudent plant spending enters the rate base and earns an authorized return, and earnings per share rose from $1.38 in 2016 to $2.36 in 2025 because of it. We therefore split the spending in two. Spending equal to depreciation ($32.5 million in 2025) is treated as the cost of keeping the system and its earning base intact. Spending above depreciation is treated as new investment: we charge every dollar of it in the year it is spent and credit only the regulated return it earns afterwards. On that basis the cash the business produced before paying lenders was $1.53 a share in 2019, $1.99 in 2023, $2.42 in 2024 and $2.45 in 2025. This counts pension contributions ($5.4 million in 2025) as a real cost, excludes non-cash construction-period equity income, and excludes a one-time $9.0 million recovery of costs from the PFAS manufacturers' settlement in 2024. Earning power today. Last year's cash generation per share grew only 1.2%. We expect a step up in 2026 because of the dated New Jersey rate order, and the first half of 2026 supports this: net income rose to $25.4 million from $20.3 million. Operating cash flow fell in the half, but that is explained by bill-paying timing and a one-time $3.3 million customer bill credit, not by weaker earnings. Utility earnings follow a saw-tooth pattern. They jump when new rates take effect and erode as costs rise until the next rate case; 2023 shows the erosion, when higher interest costs, along with the absence of a one-time 2022 gain on selling a subsidiary, cut earnings per share to $1.76 from $2.39. So we value a cycle-average level rather than the 2026 peak of roughly $2.90 a share. Base case ($30.35 per share). Cash generation of $2.70 a share before lenders, held flat for as long as the franchise lasts. What keeps it going is the regulated return on a rate base kept intact by replacement spending; the company has a 129-year operating record and exclusive service territories. On top of that we credit the disclosed 2026-2028 capital plan of $506 million, about $400 million of it above depreciation. That includes roughly $255 million for PFAS treatment at the CJO plant, required to meet drinking-water limits, plus the RENEW main-replacement program at about $12 million a year. We assume it earns a blended 7.3% return (9.6% on the 54.25% equity share plus the cost of debt) starting a year after it is spent. The surcharge mechanisms approved in February 2026, which let Middlesex recover qualifying PFAS and resiliency spending through semi-annual filings until October 2028, support that short delay. Because the authorized return is only a little above our 6% discount rate, the program adds just $3.98 a share. We credit no rate-base growth beyond 2028, because it depends on future spending decisions and rate orders that do not yet exist. The business is worth about $918 million ($48.98 a share). Bear case ($21.69 per share). Rate relief only restores past erosion, and lag keeps cash generation at the 2024-2025 average of $2.35 a share. The PFAS and main-replacement program earns only 9.5% on equity (the level Delaware just granted Tidewater), with a two-year delay before it earns anything. The fee-based contract to operate Perth Amboy's water and wastewater systems, about 4% of 2025 revenue, expires in December 2028; it sits outside the regulated earning base and its loss is absorbed within this lower level. The business is worth about $755 million ($40.32 a share). Even this case covers its interest bill (about $13.5 million in 2025) more than three times over. Bull case ($36.70 per share). The new surcharge mechanisms shorten the lag enough that the 2026 run-rate of about $2.90 a share holds as the cycle average. Investment above depreciation continues after 2028 at the ten-year average of $57 million a year until 2035, earning the full authorized return a year after it is spent. The business is worth about $1,037 million ($55.33 a share). Debt. At December 31, 2025 the company owed $386.7 million of long-term debt, $28.25 million of short-term bank notes, $25.5 million of refundable developer advances and $1.3 million of preferred stock, against $2.8 million of cash: $439.0 million in total. Most of this debt is long-dated at low fixed rates; New Jersey and Delaware state revolving fund loans run as low as 0%, and only about $8 million a year falls due through 2030. Cash interest was about 3.6% of average debt, against our 6% benchmark. We credit the present value of that saving over an assumed 15-year remaining life ($90.1 million), which reduces the effective debt to about $349 million, or $18.63 a share. Each case is worth the business value less that $349 million: $406 million in the bear case, $569 million in the base case and $688 million in the bull case. No maturity or covenant materially threatens any case. The $506 million capital plan will be funded with new debt and new shares, and we have charged its full cost as cash spending rather than predicting the financing mix. Changes since our previous estimate. We previously valued the company at $9.78 / $34.73 / $58.31 using earnings per share and different discount rates for each case. We now discount everything at the same 6% and charge actual plant spending in cash. That narrows the range: the bear case rises because the return on invested capital is set by regulators under state law, and the bull case falls because new investment earning only slightly above 6% adds little value. What would make this wrong. The value rests on New Jersey continuing to grant returns near 9.5-9.6% and allowing the $255 million PFAS plant into rates promptly. A disallowance, a cut in authorized return, or a long delay would push value toward the bear case. Customer bills are rising quickly, and the PFAS manufacturers' settlement money goes to customers, not shareholders. We left out two possible upsides because we could not quantify them from the filings: the eventual end of tax-reform-related deferred-tax refunds to customers, and any acquisition of municipal systems beyond the 2025 Ocean View purchase.